King's Research Portal

DOI:

[10.1016/j.ejpn.2017.09.001](https://doi.org/10.1016/j.ejpn.2017.09.001)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Rossor, T., & Lim, M. J. (2017). Immune-mediated neurological syndromes: old meets new. *European Journal of Paediatric Neurology*. <https://doi.org/10.1016/j.ejpn.2017.09.001>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Immune-mediated neurological syndromes: old meets new

Dr Thomas Rossor, Dr Ming J. Lim

PII: S1090-3798(17)31868-8

DOI: [10.1016/j.ejpn.2017.09.001](https://doi.org/10.1016/j.ejpn.2017.09.001)

Reference: YEJPN 2301

To appear in: *European Journal of Paediatric Neurology*

Received Date: 1090-3798 1090-3798

Revised Date: 1090-3798 1090-3798

Accepted Date: 1090-3798 1090-3798

Please cite this article as: Rossor T, Lim MJ, Immune-mediated neurological syndromes: old meets new, *European Journal of Paediatric Neurology* (2017), doi: 10.1016/j.ejpn.2017.09.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Immune-mediated neurological syndromes: old meets new

Dr Thomas Rossor¹, Dr Ming J Lim^{1, 2}

¹Children's Neurosciences, Evelina London Children's Hospital @ Guy's and St. Thomas' NHS Foundation Trust, London, King's Health Partners Academic Health Science Centre, UK

²Faculty of Life Sciences and Medicine, King's College London, UK

Correspondence to: Dr Ming Lim

Children's Neurosciences, Evelina Children's Hospital @ Guys and St Thomas' NHS Foundation Trust, Kings Health Partners Academic Health Science Centre
Floor 2, Becket House, Westminster Bridge Road, London SE1 7EH
Tel: 0044(0)20 71884002 E-mail: Ming.Lim@gstt.nhs.uk

The discovery of a range of brain and glial directed autoantibodies has allowed clinicians to associate these antibodies to specific neurological syndromes;⁽¹⁾ and have additionally started to unify past and present clinically identical neurological syndromes. For example, the intriguing polysymptomatic eponymous Sébire encephalitis is now acknowledged by many to be anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.⁽²⁾ 50 years after Lord Brain first described Hashimoto's Encephalopathy (HE), a disorder characterized by diverse neurological dysfunction with associated elevated anti-thyroid antibodies, Chen et al. describe a child with an inflammatory encephalopathy in whom both anti-thyroid and myelin oligodendrocyte glycoprotein (MOG) autoantibodies were identified.⁽³⁾

Whilst there has been agreement amongst clinicians on the existence of a neurologic syndrome associated with thyroid antibodies; and its clinical response to steroid therapy alongside association with other autoimmune diseases suggesting an immune mediated central nervous system disorder, there remains significant doubt of the pathogenic role of thyroid antibodies.⁽⁴⁾ Similarly, although MOG antibody appear to mediate clinical and radiological phenotype of demyelination that is distinguishable from multiple sclerosis,⁽⁵⁾ the precise mechanistic effects of antibodies are not resolved. Nonetheless, it is plausible that MOG, expressed in the outermost lamella of the myelin sheath, may either be a primary target of autoimmunity or may become exposed in any brain inflammation, particularly in those in whom myelin inflammation is ongoing. Thus, the main clinical question this child with a neurological syndrome and two antibodies identified is if the patient may have HE and MOG-associated brain inflammation concurrently or either HE or MOG associated brain inflammation with the respective other antibody not contributing to the neurologic syndrome.

The co-occurrence of auto-immune syndromes in patients is recognised and may target multi-organs or a single organ in multiple ways. Examples of brain directed autoimmunity co-occurring with systemic auto-immunity, as has been proposed in this case, and/or across a timeline are reported and would not be novel to clinicians. Importantly, we are starting to recognise that some co-occurrence may cluster more

frequently such as myasthenia gravis with neuromyelitis optica;⁽⁶⁾ or more specifically, MOG-antibody associated demyelination syndrome that may occur before, during or after anti-NMDAR encephalitis.⁽⁷⁾

The specificity of thyroid antibodies in predicting a neurological syndrome is limited as these autoantibodies are frequently also present in the general population without thyroid associated disease.⁽⁴⁾ A positive thyroid auto-antibody in the presence of encephalopathy may lead to the clinical diagnosis of HE, potentially in the context of a yet to be tested or identified pathogenic brain directed autoimmunity. The case reported by Chen et al⁽³⁾, alongside previously reported cases of HE sharing very distinct phenotypic similarity to cases of anti-MOG antibody associated demyelination, as reviewed by the authors, raises the important question if a subset of cases of HE are actually MOG antibody mediated disease.

Future identification of other neuronal surface antibodies are likely to define the precise target of autoimmunity in other previously recognised neurological syndromes. Importantly, care still needs to be given to establishing the clinical relevance and treatment implications of identification of these antibodies, including MOG antibodies.

Disclosures: Dr Ming Lim receives research grants from Action Medical Research, DES society, GOSH charity, NIHR, MS Society, SPARKS charity and; receives research support grants from the London Clinical Research Network and Evelina Appeal; has received consultation fees from CSL Behring; received travel grants from Merck Serono; and awarded educational grants to organize meetings by Novartis, Biogen Idec, Merck Serono and Bayer. Dr Thomas Rossor has no conflicts of interest.

References

1. Lim M, Gorman M. Autoimmune neurologic disorders in children. *Handb Clin Neurol*. 2016; 133: 485-510.
2. Sebire G. In search of lost time from "Demonic Possession" to anti-N-methyl-D-aspartate receptor encephalitis. *Ann Neurol*. 2010; 67: 141-142; author reply 142-143.
3. Chen K-A, Brilot F, Dale RC, Lafferty AR, Andrews PI. Hashimoto's encephalopathy and anti-MOG antibody encephalitis: 50 years after Lord Brain's description. *Eur J Paediatr Neurol* (In Press).
4. Schiess N, Pardo CA. Hashimoto's encephalopathy. *Ann N Y Acad Sci*. 2008; 1142: 254-265.
5. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. *Neurology*. 2017.
6. Jarius S, Paul F, Franciotta D, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. *Mult Scler*. 2012; 18: 1135-1143.
7. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. *Ann Neurol*. 2014; 75: 411-428.